Imagion Biosystems Limited (Imagion, ASX:IBX), is pleased to provide shareholders and interested parties an outline of its operational objectives as it moves toward first-in-human testing after the completion of its $12 million IPO and subsequent ASX listing.
Read the 12 July 2017 ASX Announcement.
[Video] Shareholder Webinar Recording | August 15, 2024
August 22, 2024
Open a copy of this presentation deck from our ASX announcement HERE. Video transcript: Mel: Good morning, everyone. Thank you for attending the investor presentation